Samuel Isaly, Orbimed Advisors Disclose Position in Post-IPO Relypsa

Sam Isaly’s Orbimed Advisors disclosed its position in Relypsa Inc (NASDAQ:RLYP), a company that recently conducted its IPO. Orbimed reported holding around 3.2 million of Series B-1 Preferred Stock, and some 3.7 million of Series C-2 Preferred Stock. At the same time, Orbimed holds warrants to purchase stock, equal to over 1.7 million shares of Series C-1 Preferred Stock.

Disclosure: none

Recommended Reading:

Cliff Asness, AQR Capital Like Exxon Too, Also Bullish on Chevron

Jeff Smith, Starboard Trim Stake in Emulex

Pentwater Capital Management Adds Stewart Enterprises to Equity Portfolio